Last reviewed · How we verify

DEFACTINIB — Competitive Intelligence Brief

DEFACTINIB (DEFACTINIB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed MEK1/2, ERK1/2, FAK, Pyk2 Small molecule Live · refreshed every 30 min

Target snapshot

DEFACTINIB (DEFACTINIB). Avutometinib inhibits MEK1/2 and ERK1/2 phosphorylation, while defactinib inhibits FAK and Pyk2, enhancing anti-tumor effects when combined.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DEFACTINIB TARGET DEFACTINIB marketed MEK1/2, ERK1/2, FAK, Pyk2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DEFACTINIB — Competitive Intelligence Brief. https://druglandscape.com/ci/defactinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: